NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

XENE

Xenon Pharmaceuticals Inc

Jul 11 • 04:00PM ET

32.21

Dollar change -0.77
Percentage change -2.33	%

Healthcare • Biotechnology • Canada • NASD

Peers: CRSP ONC ARGX ARWR AKRO EDIT ACAD AGEN KURA ARDX

| Held by: IWM IWO IBB VHT SPDW NUSC ESML VT RSSL SBIO

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-3.22	Insider Own	3.05%	Shs Outstand	76.59M	Perf Week	-3.16%
Market Cap	2.47B	Forward P/E	-	EPS next Y	-4.39	Insider Trans	-2.30%	Shs Float	74.39M	Perf Month	0.16%
Enterprise Value	1.93B	PEG	-	EPS next Q	-0.99	Inst Own	97.56%	Short Float	9.93%	Perf Quarter	1.96%
Income	-251.45M	P/S	329.55	EPS this Y	-33.45%	Inst Trans	0.76%	Short Ratio	5.91	Perf Half Y	-20.94%
Sales	7.50M	P/B	3.50	EPS next Y	-9.41%	ROA	-30.25%	Short Interest	7.39M	Perf YTD	-17.83%
Book/sh	9.19	P/C	4.50	EPS next 5Y	-14.00%	ROE	-31.60%	52W High	46.00 -29.98%	Perf Year	-17.94%
Cash/sh	7.16	P/FCF	-	EPS past 3/5Y	-19.41% -14.28%	ROIC	-35.35%	52W Low	26.74 20.46%	Perf 3Y	-3.30%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	65.07%	Volatility	4.21% 3.96%	Perf 5Y	144.02%
Dividend TTM	-	EV/Sales	257.42	EPS Y/Y TTM	-18.58%	Oper. Margin	-3906.60%	ATR (14)	1.32	Perf 10Y	226.01%
Dividend Ex-Date	-	Quick Ratio	17.66	Sales Y/Y TTM	-100.00%	Profit Margin	-3352.61%	RSI (14)	50.43	Recom	1.05
Dividend Gr. 3/5Y	- -	Current Ratio	17.66	EPS Q/Q	-33.82%	SMA20	-0.03%	Beta	1.17	Target Price	55.18
Payout	-	Debt/Eq	0.01	Sales Q/Q	-	SMA50	-0.03%	Rel Volume	0.47	Prev Close	32.98
Employees	327	LT Debt/Eq	0.01	Earnings	May 12 AMC	SMA200	-13.41%	Avg Volume	1.25M	Price	32.21
IPO	Nov 05, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	7.39% 176.31%	Trades		Volume	588,886	Change	-2.33%

Date	Action	Analyst	Rating Change	Price Target Change
May-07-25	Initiated	Chardan Capital Markets	Buy	$55
Feb-11-25	Initiated	Deutsche Bank	Buy	$67
Oct-10-24	Resumed	Raymond James	Outperform	$50
Oct-01-24	Initiated	H.C. Wainwright	Buy	$53
Jan-04-24	Initiated	Citigroup	Buy	$62
Dec-08-23	Initiated	Robert W. Baird	Outperform	$63
Oct-24-23	Resumed	Cantor Fitzgerald	Overweight
Apr-25-23	Initiated	Cantor Fitzgerald	Overweight	$58
Dec-14-22	Initiated	Goldman	Buy	$60
Dec-12-22	Initiated	Cowen	Outperform
Nov-28-22	Initiated	Wells Fargo	Overweight	$50
Oct-19-22	Initiated	Raymond James	Outperform	$52
Aug-29-22	Initiated	BofA Securities	Buy	$45
Jul-21-22	Initiated	JP Morgan	Overweight	$55
Oct-28-21	Initiated	RBC Capital Mkts	Outperform	$43
Oct-02-20	Initiated	SVB Leerink	Outperform	$22
Jul-21-20	Initiated	Needham	Buy	$22
Jun-01-20	Resumed	Jefferies	Buy	$23
Mar-25-20	Initiated	Wedbush	Outperform	$23
Jan-08-20	Initiated	William Blair	Outperform

Show Previous Ratings

Jul-02-25 03:20AM	RBC Raises Xenon Price Target, Cites Phase III Optimism for Epilepsy Drug (Insider Monkey)
Jun-27-25 04:01PM	Xenon Joins the Russell 3000 and Russell 2000 Indexes (GlobeNewswire)
Jun-26-25 04:01PM	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-24-25 08:30AM	Xenon Announces Appointment of Darren Cline as Chief Commercial Officer (GlobeNewswire)
Jun-11-25 11:30AM	Xenon Pharmaceuticals (XENE) Up 8.7% Since Last Earnings Report: Can It Continue? (Zacks)
04:01PM	Loading…
Jun-03-25 04:01PM	Xenon to Present at the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-30-25 04:01PM	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-14-25 04:01PM	Xenon to Present at the 2025 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
08:18AM	Why Xenon Pharmaceuticals Inc. (XENE) Declined on Tuesday (Insider Monkey)
May-13-25 12:07PM	Xenon Q1 Loss Narrower Than Expected, Pipeline Development in Focus (Zacks) -17.43%
03:09AM	Xenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings Call Highlights: Strong Financial Position ... (GuruFocus.com)
May-12-25 04:10PM	Xenon Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Xenon Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-09-25 09:24AM	Xenon Pharmaceuticals Inc (XENE) Q1 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
May-07-25 08:00AM	Rare Stock Picks In April 2025 - From 16 Discerning Analysts (Seeking Alpha)
04:01PM	Loading…
May-05-25 04:01PM	Xenon to Report Q1 2025 Financial Results on May 12, 2025 (GlobeNewswire) -6.29%
09:55AM	Wall Street Analysts See a 48.15% Upside in Xenon Pharmaceuticals (XENE): Can the Stock Really Move This High? (Zacks)
May-02-25 04:42PM	Xenon Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Apr-18-25 03:36AM	Xenon- A Later Stage Story (Seeking Alpha)
Apr-04-25 04:23PM	Xenon Pharmaceuticals Looks Attractive Before Epilepsy Data (Seeking Alpha)
08:30AM	Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025 (GlobeNewswire)
Mar-12-25 04:01PM	Xenon to Present at Stifel 2025 Virtual CNS Forum (GlobeNewswire)
Feb-28-25 02:36AM	Xenon Pharmaceuticals Inc (XENE) Q4 2024 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com)
Feb-27-25 04:18PM	Xenon Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update (GlobeNewswire)
Feb-26-25 07:28AM	What To Expect From Xenon Pharmaceuticals Inc (XENE) Q4 2024 Earnings (GuruFocus.com)
Feb-25-25 04:01PM	Xenon to Present at the 45th Annual TD Cowen Healthcare Conference (GlobeNewswire)
Feb-20-25 04:01PM	Xenon to Report Q4 and Full Year 2024 Financial Results on February 27, 2025 (GlobeNewswire)
Jan-13-25 08:30AM	Xenon Outlines Key Corporate Milestone Opportunities for 2025 (GlobeNewswire)
Jan-07-25 08:30AM	Xenon to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
11:30AM	Loading…
Dec-12-24 11:30AM	Xenon Pharmaceuticals (XENE) Up 2.4% Since Last Earnings Report: Can It Continue? (Zacks) -8.19%
Dec-06-24 04:01PM	Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024 (GlobeNewswire)
Nov-25-24 08:30AM	Xenon to Showcase New Long-Term Azetukalner Data at AES 2024 (GlobeNewswire)
Nov-22-24 09:30AM	JPMorgan Selects These 2 Stocks as Must-Haves for 2025 (TipRanks)
Nov-13-24 04:01PM	Xenon to Present at Upcoming Investor Conferences (GlobeNewswire)
02:17AM	Xenon Pharmaceuticals Inc (XENE) Q3 2024 Earnings Call Highlights: Strategic Advancements and ... (GuruFocus.com)
Nov-12-24 04:07PM	Xenon Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Xenon Reports Q3 2024 Financial Results and Business Update (GlobeNewswire)
Nov-11-24 07:06AM	Earnings To Watch: Xenon Pharmaceuticals Inc (XENE) Reports Q3 2024 Result (GuruFocus.com)
Nov-05-24 04:01PM	Xenon to Report Q3 2024 Financial Results on November 12, 2024 (GlobeNewswire)
Oct-09-24 05:54PM	Xenon Pharmaceuticals Inc (XENE) Q2 2024 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com)
Oct-02-24 04:28PM	Xenon to Present at BofA Securities 2024 CNS Therapeutics Virtual Conference (GlobeNewswire)
Sep-09-24 08:30AM	Xenon Showcases Azetukalner Data at 15th European Epilepsy Congress (GlobeNewswire)
Sep-05-24 01:12AM	Xenon Pharmaceuticals Inc. (XENE): Among the Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Sep-02-24 06:05PM	10 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-21-24 10:46AM	Xenon (XENE) Focuses on Neuro Candidate Amid Pipeline Woe (Zacks)
Aug-12-24 08:30AM	Xenon Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as Chief Operating Officer (GlobeNewswire)
Aug-09-24 10:19AM	Xenon (XENE) Q2 Earnings Miss, Pipeline in Focus, Stock Down (Zacks)
Aug-08-24 09:59PM	XENE Stock Earnings: Xenon Pharmaceuticals Misses EPS for Q2 2024 (InvestorPlace)
04:26PM	Xenon Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Xenon Reports Q2 2024 Financial Results and Business Update (GlobeNewswire)
Aug-01-24 04:01PM	Xenon to Report Q2 2024 Financial Results on August 8, 2024 (GlobeNewswire)
Jun-27-24 03:54PM	Is Xenon Pharmaceuticals Inc. (XENE) One of the Best Healthcare Stocks Under $50? (Insider Monkey)
Jun-05-24 04:01PM	Xenon Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference (GlobeNewswire)
May-28-24 08:30AM	Xenon Pharmaceuticals Presents Data from Phase 2 X-NOVA Clinical Trial of Azetukalner in Major Depressive Disorder at the American Society of Clinical Psychopharmacology 2024 Annual Meeting (GlobeNewswire)
May-27-24 06:55PM	Hedge Funds are Racking Up Shares of This Healthcare Stock (Insider Monkey)
06:13PM	7 Best Mid-Cap Healthcare Stocks To Buy Now (Insider Monkey)
May-10-24 05:03PM	Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q1 2024 Earnings Call Transcript (Insider Monkey)
12:56PM	Xenon Pharmaceuticals Inc (XENE) Reports Increased Losses in Q1 2024, Despite Advancements in ... (GuruFocus.com)
08:17AM	Xenon (XENE) Q1 Earnings Beat Estimates, Pipeline in Focus (Zacks)
07:29AM	Wedbush Trims Xenon Pharmaceuticals' Price Target to $50 From $51, Maintains Outperform Rating (MT Newswires)
May-09-24 08:57PM	XENE Stock Earnings: Xenon Pharmaceuticals Beats EPS for Q1 2024 (InvestorPlace)
04:29PM	Xenon Pharmaceuticals Q1 Net Loss Narrows (MT Newswires)
04:17PM	Xenon Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Xenon Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-24 04:01PM	Xenon Pharmaceuticals to Present at the BofA Securities Health Care Conference 2024 (GlobeNewswire)
May-07-24 04:01PM	Xenon Pharmaceuticals to Present at the 2024 RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
May-06-24 12:00PM	What Makes Xenon Pharmaceuticals (XENE) a New Buy Stock (Zacks)
May-02-24 04:01PM	Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss First Quarter 2024 Financial Results and Provide Corporate Update (GlobeNewswire)
Apr-16-24 08:30AM	Xenon Pharmaceuticals Showcases XEN1101 at the American Academy of Neurology 2024 Annual Meeting (GlobeNewswire)
Apr-10-24 08:30AM	Xenon Pharmaceuticals to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference (GlobeNewswire)
Apr-04-24 04:01PM	Xenon Pharmaceuticals to Present at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-12-24 04:01PM	Xenon Pharmaceuticals to Present at Stifel 2024 Virtual CNS Days (GlobeNewswire)
Mar-08-24 11:55PM	Insider Sell: EVP, Strategy & Innovation Sherrington Robin Sells 7,137 Shares of Xenon ... (GuruFocus.com)
Mar-05-24 04:01PM	Xenon Pharmaceuticals to Present at Leerink Partners Global Biopharma Conference 2024 (GlobeNewswire)
Mar-02-24 08:37AM	Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-01-24 08:35AM	Xenon (XENE) Q4 Earnings Top Estimates, Pipeline in Focus (Zacks)
Feb-29-24 04:34PM	Xenon Pharmaceuticals Inc (XENE) Reports Full Year and Q4 2023 Financial Results (GuruFocus.com)
04:13PM	Xenon Pharmaceuticals: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
Feb-22-24 04:01PM	Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update (GlobeNewswire)
Feb-21-24 10:08PM	3 Biotech Stocks That Could Be Multibaggers in the Making: February Edition (InvestorPlace)
Jan-23-24 08:36AM	Here's Why You Should Add Xenon (XENE) to Your Portfolio Now (Zacks)
Jan-19-24 09:55AM	Wall Street Analysts Think Xenon Pharmaceuticals (XENE) Could Surge 25.76%: Read This Before Placing a Bet (Zacks)
Jan-08-24 08:00AM	Xenon Pharmaceuticals Outlines Key Milestone Opportunities for 2024 (GlobeNewswire) +5.23%
Jan-03-24 08:30AM	Xenon Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-05-23 01:31PM	5 Most Promising Stocks to Buy According to Hedge Funds (Insider Monkey)
Dec-04-23 04:16PM	Xenon Pharmaceuticals Announces Closing of $345.0 Million Upsized Public Offering Including Full Exercise of the Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Dec-02-23 12:01PM	Xenon Pharmaceuticals Provides Updates on Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2023) (GlobeNewswire)
Nov-29-23 10:51PM	Xenon Pharmaceuticals Announces Pricing of Upsized $300.0 Million Public Offering (GlobeNewswire) +8.39%
04:03PM	Xenon Pharmaceuticals Announces Proposed Public Offering (GlobeNewswire)
Nov-28-23 11:17AM	Xenon (XENE) Up on Top-Line Data From MDD Drug Phase II Study (Zacks)
Nov-27-23 04:28PM	The Unexpected Depression Drug News That Sent Xenon Pharmaceuticals Soaring (Investor's Business Daily) +17.78%
12:19PM	Cerence, Roivant Sciences fall; Xenon Pharmaceuticals, Shopify rise, Monday, 11/27/2023 (Associated Press Finance)
07:30AM	UPDATE 1-Canada's Xenon Pharma's depression drug fails to meet main goal in study (Reuters)
07:09AM	Xenon Pharmaceuticals' depression drug fails to meet main goal in study (Reuters)
07:00AM	Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-of-Concept X-NOVA Clinical Trial of XEN1101 in Major Depressive Disorder (MDD) (GlobeNewswire)
04:21AM	Xenon drug misses main goal of depression study (BioPharma Dive)
Nov-09-23 05:14PM	Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Q3 2023 Earnings Call Transcript (Insider Monkey) -6.69%
04:03PM	Xenon Pharmaceuticals Provides Update on Partnered Program with Neurocrine Biosciences (GlobeNewswire)

Xenon Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It develops therapeutics to improve the lives of patients with neurological disorders, including rare central nervous system (CNS) conditions. The company's products include XEN496, XEN1101, XEN901 and XEN007. Xenon Pharmaceuticals was founded by Simon Neil Pimstone, Johannes J. P. Kastelein and Michael R. Hayden on November 5, 1996 and is headquartered in Burnaby, Canada.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
GANNON STEVEN	Director	Jun 05 '25	Sale	30.48	3	91	7,141	Jun 06 05:58 PM
GANNON STEVEN	Director	May 14 '25	Option Exercise	12.57	5,144	64,660	7,144	May 16 05:59 PM
MORTIMER IAN	PRESIDENT & CEO	Jan 24 '25	Option Exercise	17.76	22,468	399,032	53,770	Jan 27 08:28 PM
MORTIMER IAN	PRESIDENT & CEO	Jan 27 '25	Option Exercise	17.76	16,315	289,754	46,468	Jan 27 08:28 PM
MORTIMER IAN	PRESIDENT & CEO	Jan 23 '25	Option Exercise	17.76	16,217	288,014	47,519	Jan 27 08:28 PM
MORTIMER IAN	PRESIDENT & CEO	Jan 24 '25	Sale	40.20	22,468	903,214	31,302	Jan 27 08:28 PM
MORTIMER IAN	PRESIDENT & CEO	Jan 27 '25	Sale	40.50	16,315	660,806	31,302	Jan 27 08:28 PM
MORTIMER IAN	PRESIDENT & CEO	Jan 23 '25	Sale	40.08	16,217	649,977	31,302	Jan 27 08:28 PM
IAN MORTIMER	Officer	Jan 27 '25	Proposed Sale	40.50	16,315	660,823		Jan 27 08:25 PM
IAN MORTIMER	Officer	Jan 24 '25	Proposed Sale	40.20	22,468	903,299		Jan 24 05:13 PM
IAN MORTIMER	Officer	Jan 23 '25	Proposed Sale	40.08	16,217	649,928		Jan 23 06:34 PM
AULIN SHERRY	Chief Financial Officer	Dec 18 '24	Option Exercise	10.79	25,334	273,393	16,000	Dec 19 06:57 PM
AULIN SHERRY	Chief Financial Officer	Dec 18 '24	Sale	41.21	18,709	770,912	0	Dec 19 06:57 PM
SHERRY AULIN	Officer	Dec 18 '24	Proposed Sale	41.21	18,709	770,909		Dec 18 05:50 PM
PATOU GARY	Director	Nov 22 '24	Option Exercise	10.24	6,586	67,429	27,073	Nov 22 07:48 PM
PATOU GARY	Director	Nov 22 '24	Sale	41.08	4,891	200,947	23,573	Nov 22 07:48 PM
GARY PATOU	Director	Nov 22 '24	Proposed Sale	41.08	4,891	200,932		Nov 22 06:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

XENE

Xenon Pharmaceuticals Inc

Upgrade your FINVIZ experience